Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)
A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
Sponsor: Celgene Corporation
Terminated
The study has been suspended for slower than anticipated enrollment to date.
Other terminated trials from Celgene Corporation
- Multiple Myeloma · Phase PHASE1/PHASE2 · Oct 2025
- Leukemia, Myeloid, Acute · Phase PHASE1 · Jul 2025
- Relapsed/Refractory Multiple Myeloma · Phase PHASE2 · Jul 2025
- Multiple Myeloma · Jun 2025
- Multiple Sclerosis · Phase PHASE3 · May 2025
More terminations from Celgene Corporation
Other Neuropathy trials with similar outcome
This PHASE2 trial investigates Neuropathy and Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) and is currently terminated or withdrawn. Celgene Corporation leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Feb 2017 — May 2018 [monthly]
Suspended PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE2
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Dartmouth-Hitchcock Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .